Biochemical and renal-metabolic profiles distinguishing primary aldosteronism from essential hypertension: a systematic review and meta-analysis with implications for endocrine hypertension screening - Report - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Differentiating Primary Aldosteronism from Essential Hypertension: A Systematic Review and Meta-Analysis of Biochemical and Renal-Metabolic Profiles for Endocrine Hypertension Screening
Clinical Report: Differentiating Primary Aldosteronism from Essential Hypertension
Overview
This systematic review and meta-analysis evaluated the biochemical and renal-metabolic profiles of primary aldosteronism (PA) compared to essential hypertension (EH). Key findings indicate significant differences in serum potassium, sodium, and uric acid levels.
Background
Primary aldosteronism (PA) is a leading cause of secondary hypertension, affecting 5%-10% of the hypertensive population. Despite its prevalence, PA remains under-recognized, particularly in patients with stage 1 hypertension, as indicated by recent studies. Differentiating between unilateral and bilateral PA is crucial for determining appropriate treatment strategies.
Data Highlights
Measure
PA vs Controls
Mean Difference
Serum Potassium
SMD = −1.15
−0.49 mmol/L
Sodium
SMD = 0.51
+1.20 mmol/L
Uric Acid
SMD = −0.23
−20.7 μmol/L
Key Findings
PA is associated with significantly lower serum potassium compared to EH.
PA shows higher serum sodium levels relative to controls.
Uric acid levels are lower in PA compared to EH.
Unilateral PA exhibits lower potassium levels than bilateral PA.
Urinary albumin-to-creatinine ratio (UACR) is elevated in PA.
Clinical Implications
Routine renal evaluations for patients with hypertension should include urinary albumin measurements alongside traditional filtration markers.
Conclusion
The findings highlight distinct biochemical profiles of PA.
